Dinutuximab Beta

Department of Health and Social Care written question – answered on 21st June 2018.

Alert me about debates like this

Photo of Helen Hayes Helen Hayes Labour, Dulwich and West Norwood

To ask the Secretary of State for Health and Social Care, what assessment he has made of accuracy of NICE’s decision not to fund Dinutuximab Beta for patients with Neuroblastoma.

Photo of Helen Hayes Helen Hayes Labour, Dulwich and West Norwood

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that patients with Neuroblastoma are able to access appropriate treatments on the NHS.

Photo of Helen Hayes Helen Hayes Labour, Dulwich and West Norwood

To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the provision of medicines on the NHS for people with Neuroblastoma.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

Through its technology appraisal programme, the National Institute for Health and Care Excellence (NICE) develops authoritative, independent and evidence-based recommendations for the National Health Service on whether drugs and treatments represent a clinically and cost effective use of NHS resources. NICE develops technology appraisal guidance for the NHS on all new cancer drugs, including for neuroblastoma, and NHS England is legally required to fund cancer drugs recommended in NICE technology appraisal guidance.

NICE is currently appraising the drug dinutuximab beta for use in the treatment of high-risk neuroblastoma and has not yet issued final guidance. NICE recently consulted on its draft recommendations and will take the comments it received fully into account in developing its final guidance.

NICE has also been asked to appraise the drug dinutuximab for use in the treatment of high-risk neuroblastoma but the manufacturer asked for the drug’s marketing authorisation to be withdrawn because of supply issues and NICE’s appraisal has now been suspended.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.